Search results
Showing 1 to 6 of 6 results for esketamine
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA899
help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36 . Any explanatory...
Past technology appraisal appeals and decisions
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.